Drug intelligence / Profile preview

CT-005

Development stage
Unknown
Lead developer
Coagulant Therapeutics
Modality
Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01

Overview

CT-005 is a llama-derived nanobody therapeutic developed by Coagulant Therapeutics that targets Activated Protein C (APC). As a nanobody, it is a small (approximately 15 kDa) antibody fragment designed to bind specifically to the exosite of APC, thereby inhibiting its anticoagulant function. This mechanism is intended to restore hemostatic balance in patients with severe bleeding disorders or acute coagulopathies. CT-005 is part of a broader APC-targeting program that leverages a proprietary nanobody library to address conditions where the coagulation cascade is dysregulated. It is currently in Phase 1 clinical development, with potential applications in treating trauma-induced coagulopathy, hemophilia, ischemia, and sepsis.

Other names
APC nanobody
02

Targets

APC (Activated protein C)

Beyond the preview

Go deeper on CT-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-005.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call